Fresenius stock pre-market at EUR 43.56: minus 0.23 percent
Published on 10/07/2026 at 08:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Fresenius stock was at EUR 43.56 pre-market at 8:22 a.m. CEST on October 7, 2026. The price was down 0.23 percent versus the Lang & Schwarz prior close of EUR 43.66 on October 6, 2026.
Pre-market trading
The Lang & Schwarz indication puts Fresenius stock below the previous trading day's close ahead of the Xetra open. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of Fresenius stock.
mAbxience fully acquired
In a release dated October 1, 2026, Fresenius said it had acquired the remaining 45 percent of mAbxience from Insud Pharma and Invim Corporativo for total consideration of up to EUR 750 million, including a contingent EUR 50 million payment tied to site approvals. The transaction was signed and completed on September 30, 2026, with no regulatory approvals required.
Guidance unchanged
Fresenius said the transaction is expected to be immediately accretive to group core earnings per share. The company also said its full-year 2026 guidance and its 2030 Biopharma ambition remain unchanged.
